Home › Novartis buys remaining rights to GSK treatment in deal up to $1 billion
 

Keywords :   


Novartis buys remaining rights to GSK treatment in deal up to $1 billion

2015-08-21 09:12:45| Biotech - Topix.net

Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline. Basel-based Novartis will make an initial upfront payment of $300 million to GSK for the acquisition of the compound and a further $200 million payable following the start of a phase III study in MS by Novartis.

Tags: to rights treatment deal

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Wind Speed Probabilities Number 14
07.11Hurricane Rafael Forecast Discussion Number 14
07.11Hurricane Rafael Forecast Advisory Number 14
07.11Hurricane Rafael Public Advisory Number 14
07.11Tropical Depression Fourteen-E Graphics
07.11Tropical Depression Fourteen-E Forecast Discussion Number 3
07.11Tropical Depression Fourteen-E Wind Speed Probabilities Number 3
More »